Recurrent or Refractory Ascites – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034

 Recurrent or Refractory Ascites Market Outlook

Thelansis’s “Recurrent or Refractory Ascites Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Recurrent or Refractory Ascites treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Recurrent or Refractory Ascites Overview

Ascites refers to the abnormal accumulation of fluid within the peritoneal cavity, primarily associated with cirrhosis and often indicating the transition from compensated to decompensated cirrhosis. Refractory ascites (RA) is a term defined by the International Club of Ascites (ICA) as ascites that recurs within 4 weeks after large-volume paracentesis (LVP) and is resistant to medical therapy. Recurrent ascites, defined as ascites recurring at least three times within 12 months, impact survival differently than RA, and its effects on survival are yet unknown. Refractory ascites, occurring in 5%–10% of all patients with cirrhotic ascites, is associated with a high mortality rate, with an average 1-year survival rate of around 50%. Large-volume paracentesis, the primary treatment for refractory ascites, involves directly aspirating more than 5 liters of ascites. While LVP can rapidly control massive ascites and reduce hospital stays compared to diuretics, it does not affect the mortality rate.

 

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support

*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2024–2034)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market’s trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?
• and more…

Read more: Recurrent or Refractory Ascites – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034